Q-omics provides the consensus-scored KLHL33 profile across patient tissues and cancer cell-line models. KLHL33 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, KLHL33 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, KLHL33 RNA expression shows 19,167 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, KIRC, and LSCC as cancer lineages where KLHL33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL33 survival associations across molecular data types. KLHL33 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL33 RNA expression–survival associations across cancer types. High KLHL33 expression shows unfavorable associations in THCA, LGG and COAD, but favorable associations in KIRC, SKCM and PAAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for KLHL33 RNA expression.
This table summarizes KLHL33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KLHL33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL33 shows lower tumor expression in KIRC, THCA, BLCA, LUAD, UCEC and KICH. The KIRC box plot shows higher KLHL33 RNA expression in normal versus tumor tissue (log2 FC = −0.434, t-test p < 0.001).
This table shows molecular features associated with KLHL33 in patient tissues and cancer cell lines. In patient samples, KLHL33 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
